Intravascular recovery of VWF and FVIII following intraperitoneal injection and differences from intravenous and subcutaneous injection in mice

Haemophilia

Volumn 18, Issue 4, 2012, Pages 639-646

  Shi, Q ^a   Kuether, E L ^a   Schroeder, J A ^a   Fahs, S A ^a   Montgomery, R R ^a  

^a CHILDREN S HOSPITAL OF WISCONSIN   (United States)

Author keywords

Factor VIII; Infusion; Intraperitoneal; Von Willebrand factor

Indexed keywords

BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CIRCULATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; FACTOR VIII; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MICE; MICE, INBRED C57BL; VON WILLEBRAND FACTOR;

EID: 84863193826     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2011.02735.x     Document Type: Article

References (41)

1. Ruggeri ZM, Ware J. The structure and function of von Willebrand factor. Thromb Haemost 1992; 67: 594-9.
2. Montgomery RR, Gill JC. Interactions between von Willebrand factor and factor VIII: where did they first meet. J Pediatr Hematol Oncol 2000; 22: 269-75.
3. Ruggeri ZM, Zimmerman TS. The complex multimeric composition of factor VIII/von Willebrand factor. Blood 1981; 57: 1140-3.
4. Mannucci PM, Abildgaard CF, Gralnick HR et al. Multicenter comparison of von Willebrand factor multimer sizing techniques. Report of the factor VIII and von Willebrand factor Subcommittee. Thromb Haemost 1985; 54: 873-6.
5. Ruggeri ZM, Ware J. von Willebrand factor. FASEB J 1993; 7: 308-16.
6. Kaufman RJ, Wasley LC, Dorner AJ. Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells. J Biol Chem 1988; 263: 6352-62.
7. Kaufman RJ, Pipe SW. Regulation of factor VIII expression and activity by von Willebrand factor. Thromb Haemost 1999; 82: 201-8.
8. Kaufman RJ, Wasley LC, Davies MV, Wise RJ, Israel DI, Dorner AJ. Effect of von Willebrand factor coexpression on the synthesis and secretion of factor VIII in Chinese hamster ovary cells. Mol Cell Biol 1989; 9: 1233-42.
9. Hoyer LW. Von Willebrand's disease. Prog Hemost Thromb 1976; 3: 231-87.
10. Bolton-Maggs PH, Pasi KJ. Haemophilias A and B. Lancet 2003; 361: 1801-9.
11. Berntorp E, Boulyjenkov V, Brettler D et al. Modern treatment of haemophilia. Bull World Health Organ 1995; 73: 691-701.
12. Rodeghiero F, Castaman G. Treatment of von Willebrand disease. Semin Hematol 2005; 42: 29-35.
13. Bolton-Maggs PH, Lillicrap D, Goudemand J, Berntorp E. von Willebrand disease update: diagnostic and treatment dilemmas. Haemophilia 2008; 14(Suppl. 3): 56-61.
14. Favaloro EJ, Lloyd J, Rowell J et al. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study. Thromb Haemost 2007; 97: 922-30.
15. Dobrkovska A, Krzensk U, Chediak JR. Pharmacokinetics, efficacy and safety of Humate-P in von Willebrand disease. Haemophilia 1998; 4(Suppl. 3): 33-9.
16. Hellstern P, Kiehl R, Miyashita C et al. Factor VIII:C (FVIII:C) recovery and half-life after infusion of steam-treated high purity factor VIII concentrate in severe hemophilia A - comparison of one-stage assay, two-stage assay and a chromogenic substrate assay. Thromb Haemost 1986; 56: 353-9.
17. Liles D, Landen CN, Monroe DM et al. Extravascular administration of factor IX: potential for replacement therapy of canine and human hemophilia B. Thromb Haemost 1997; 77: 944-8.
18. Bowie EJ, Solberg LA Jr, Fass DN et al. Transplantation of normal bone marrow into a pig with severe von Willebrand's disease. J Clin Invest 1986; 78: 26-30.
19. Do H, Healey JF, Waller EK, Lollar P. Expression of factor VIII by murine liver sinusoidal endothelial cells. J Biol Chem. 1999; 274: 19587-92.
20. Doering CB, Josephson CD, Craddock HN, Lollar P. Factor VIII expression in azoxymethane-induced murine fulminant hepatic failure. Blood 2002; 100: 143-7.
21. Xu L, Nichols TC, Sarkar R, McCorquodale S, Bellinger DA, Ponder KP. Absence of a desmopressin response after therapeutic expression of factor VIII in hemophilia A dogs with liver-directed neonatal gene therapy. Proc Natl Acad Sci U S A 2005; 102: 6080-5.
22. Lamont PA, Ragni MV. Lack of desmopressin (DDAVP) response in men with hemophilia A following liver transplantation. J Thromb Haemost 2005; 3: 2259-63.
23. Kumaran V, Benten D, Follenzi A, Joseph B, Sarkar R, Gupta S. Transplantation of endothelial cells corrects the phenotype in hemophilia A mice. J Thromb Haemost 2005; 3: 2022-31.
24. Jacquemin M, Neyrinck A, Hermanns MI et al. FVIII production by human lung microvascular endothelial cells. Blood 2006; 108: 515-7.
25. Shovlin CL, Angus G, Manning RA et al. Endothelial cell processing and alternatively spliced transcripts of factor VIII: potential implications for coagulation cascades and pulmonary hypertension. PLoS ONE 2010; 5: e9154.
26. Follenzi A, Benten D, Novikoff P, Faulkner L, Raut S, Gupta S. Transplanted endothelial cells repopulate the liver endothelium and correct the phenotype of hemophilia A mice. J Clin Invest 2008; 118: 935-45.
27. Shahani T, Lavend'homme R, Luttun A, Saint-Remy JM, Peerlinck K, Jacquemin M. Activation of human endothelial cells from specific vascular beds induces the release of a FVIII storage pool. Blood 2010; 115: 4902-9.
28. Metzner HJ, Hermentin P, Cuesta-Linker T, Langner S, Muller HG, Friedebold J. Characterization of factor VIII/von Willebrand factor concentrates using a modified method of von Willebrand factor multimer analysis. Haemophilia 1998; 4(Suppl. 3): 25-32.
29. Shi Q, Wilcox DA, Fahs SA et al. Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies. J Clin Invest 2006; 116: 1974-82.
30. Brown SA, Eldridge A, Collins PW, Bowen DJ. Increased clearance of von Willebrand factor antigen post-DDAVP in Type 1 von Willebrand disease: is it a potential pathogenic process?J Thromb Haemost 2003; 1: 1714-7.
31. Haberichter SL, Balistreri M, Christopherson P et al. Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival. Blood 2006; 108: 3344-51.
32. Courtice FC, Steinbeck AW. The effects of lymphatic obstruction and of posture on the absorption of protein from the peritoneal cavity. Aust J Exp Biol Med Sci 1951; 29: 451-8.
33. Courtice FC, Steinbeck AW. Absorption of protein from the peritoneal cavity. J Physiol 1951; 114: 336-55.
34. Morris B. The effect of diaphragmatic movement on the absorption of protein and of red cells from the peritoneal cavity. Aust J Exp Biol Med Sci 1953; 31: 239-46.
35. McKay T, Zink J, Greenway CV. Relative rates of absorption of fluid and protein from the peritoneal cavity in cats. Lymphology 1978; 11: 106-10.
36. Garcia-Martin C, Chuah MK, Van DA et al. Therapeutic levels of human factor VIII in mice implanted with encapsulated cells: potential for gene therapy of haemophilia A. J Gene Med. 2002; 4: 215-23.
37. Kootstra NA, Matsumura R, Verma IM. Efficient production of human FVIII in hemophilic mice using lentiviral vectors. Mol Ther 2003; 7: 623-31.
38. Scott JP, Montgomery RR. Therapy of von Willebrand disease. Semin Thromb Hemost 1993; 19: 37-47.
39. Fischer BE, Kramer G, Mitterer A et al. Effect of multimerization of human and recombinant von Willebrand factor on platelet aggregation, binding to collagen and binding of coagulation factor VIII. Thromb Res 1996; 84: 55-66.
40. Crotts G, Park TG. Protein delivery from poly(lactic-co-glycolic acid) biodegradable microspheres: release kinetics and stability issues. J Microencapsul 1998; 15: 699-713.
41. Cohen S, Yoshioka T, Lucarelli M, Hwang LH, Langer R. Controlled delivery systems for proteins based on poly(lactic/glycolic acid) microspheres. Pharm Res 1991; 8: 713-20.